

RESPONSE TO REVIEWERS' COMMENTS

Number ID: 04429838

Manuscript Type: INVITED EDITORIAL

mTOR; Novel insight for IBD management

The authors of this manuscript express their sincere thanks to the editors and the reviewers for the critical assessment of this work. The authors have acted upon the recommendations of the reviewers which have resulted in a significant enhancement in the quality of this manuscript. All modifications incorporated in the manuscript are highlighted in yellow color. A “*point-by-point*” response to each and every comment is outlined below.

Sincerely,

Amir Hossein Abdolghaffari

MINOR REVISION

Comment 1:

Add the roles of mTOR inhibitor in IBD treatment.

Response:

Comment 2:

Discuss the mTORi induced immune tolerance in IBD for example regulating the Tregs and MDSCs.

Response:

Relevant data were included in introduction and highlighted.

Comment 3:

Add the reference : Front Oncol. 2021 Jan 8;10:611690. doi: 10.3389/fonc.2020.611690.

Response:

It was included as REF;4.

Comment 4:

References: A total of 20 references are cited, including 17 references published in the last 3 years; (5) Self-cited references: There are 2 self-cited references. The self-referencing rates should be less than 10%. Please keep the reasonable self-citations (i.e. those that are most closely related to the topic of the manuscript) and remove all other improper self-citations. If the authors fail to address the critical issue of self-citation, the editing process of this manuscript will be terminated;

Response:

Reference 3 was omitted.

Comment 5:

The language editing certificate was wrongly provided.

Response:

As we mentioned before, the corresponding author of the current MS, Dr Amirhossein Abdolghaffari, is a member of the Editorial Board of the World Journal of Pharmacology and the guest editor/reviewer of several other prestigious Journals.

Comment 6:

The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor; and (2) If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, “Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]”. And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.

Response:

Thanks. Figure 1 is original and was designed and provided by the authors.

On behalf of my co-authors, I once again express my sincere thanks to the erudite editors and reviewers for the valuable suggestions and constructive input to improve the quality of our manuscript.